SCHOFIELD, Wis., Dec. 9, 2014 /PRNewswire/ -- PuraMed
BioScience®, Inc., (OTC Pink: PMBS), a researcher,
developer, and marketer of over-the-counter (OTC) medicinal and
healthcare products, announced today that it has entered into a
5-year distribution agreement with FastFunds Financial Corporation
(OTC Pink: FFFC) of West Palm Beach,
Florida for distribution of MigraPure® H, a
hemp-based, advanced migraine relief product.
"We are pleased to have entered into an agreement with PuraMed
BioScience," said Henry Fong,
chairman and CEO of FastFunds Financial Corporation. "PuraMed's
MigraPure H migraine product is a good fit with our company's
mission to fund early-stage cannabis projects. We look forward to a
productive and profitable relationship for both companies as the
product is launched and more are developed."
The agreement gives FastFunds Financial Corporation exclusive
distribution rights in the marijuana market segment in the United States. This segment includes all
50 states, but only applies to legally permitted: medical marijuana
dispensaries, recreational marijuana retail stores, online
retailers who sell primarily marijuana and hemp products and
accessories, and other establishments with the primary business of
selling medical and/or recreational marijuana and related
accessories. FastFunds plans to market the MigraPure® H
product through its 49 percent equity ownership in WMII, Inc. and
their accessibility to a database of 1,000 medical and recreational
marijuana dispensaries in Colorado, Washington
State, and California.
"This is a great opportunity for us," said Russell Mitchell, CEO of PuraMed BioScience.
"The agreement gives people access to our products in more than
1,000 dispensaries and other distribution venues throughout
Colorado, Washington State, and California. We will be selling MigraPure
H®, our hemp-based headache formulation at these venues.
We hope to have the product on shelves early in 2015.
"In addition to MigraPure H, we also see potential in this
market segment for several other products and technologies we are
investigating. We have begun viability testing with several of the
most promising."
Preliminary findings of domestic studies show cannabinoids
relieve anxiety, post-traumatic stress disorder (PTSD), and
epilepsy symptoms. Several international studies have shown
cannabinoids can reduce cancer pain, minimize multiple sclerosis
symptoms, and have a positive impact on other disease states.
"MigraPure H allows us to make our entrance into the cannabis
space with our hemp-based homeopathic advanced headache product,"
said Mitchell. "As we promote our existing products, we will
continue to focus on the research and development of
multiple products containing hemp to treat neurologic and biologic
disorders within the over-the-counter, health and wellness
category."
About MigraPure® and
MigraPure® H
MigraPure Advanced Migraine
Relief is a sublingual feverfew and ginger gel that was clinically
tested under the name LipiGesic® M. The peppermint
flavor of this homeopathic, all-natural, over-the-counter migraine
headache pain reliever has been enhanced, but the clinically tested
active ingredients remain the same.
MigraPure stops disabling migraine pain and associated symptoms
quickly. Its patented sublingual (under-the-tongue) delivery system
efficiently delivers the active ingredients directly into the
bloodstream for fast relief. By avoiding the liver and stomach,
MigraPure's maximum strength ingredients work faster and more
effectively than traditional pills or capsules.
MigraPure's feverfew and ginger gel is non-drowsy, non-habit
forming, and not associated with rebound headaches. MigraPure has
an excellent safety profile with no reported drug interactions.
MigraPure H Advanced Headache Relief is PuraMed's most recent
all-natural, hemp-based headache reliever. The active ingredients
in MigraPure have been combined with a hemp-base to create a
powerful treatment for migraines and seizure-related headache.
Early indications show the formulation may also be effective for
tension and cluster headaches and other epilepsy symptoms.
MigraPure® H does not violate any Federal laws
pertaining to the cultivation, distribution or marketing of a
controlled or banned substance.
About PuraMed BioScience, Inc.:
PuraMed BioScience
engages in the research, development, and marketing of
non-prescription medicinal and healthcare products.
PuraMed BioScience also specializes in the development of
sublingual homeopathic medications. This type of formulation
delivers active ingredients directly into the blood stream for
faster relief and greater effectiveness with fewer side effects
than their chemical counterparts.
PuraMed BioScience believes in the value of clinical trials. The
company's goal is to build medicines that can withstand scientific
scrutiny and perform well in double-blind, placebo-controlled
clinical trials. MigraPure, clinically tested as
LipiGesic®M, showed it was effective in the treatment of
acute migraine in 64 percent of occurrences. The clinical trial
results were published in the top-tier medical journal,
Headache: The Journal of Head and Face Pain.
In addition to MigraPure and MigraPure H, PuraMed BioScience
plans to launch additional cannabinoid-enhanced, anti-inflammatory,
and anxiolytic products as it moves forward in the development of
its cannabinoid product line.
About FastFunds Financial Corporation
FastFunds
Financial Corporation ("FastFunds" or the "Company") is a holding
company that is publicly traded on the OTC Pink exchange, under the
symbol "FFFC". Through its wholly-owned subsidiaries, Cannabis
Angel, Inc., and The 420 Development Corporation, the Company is
focused on acquiring and building a portfolio of revenue producing
companies that provide ancillary services to the cannabis
industry. FastFunds does not engage in activities that
violate Federal laws.
Forward-Looking Statements:
This news release contains
forward-looking statements regarding PuraMed BioScience, Inc., and
its future business plans, which statements involve known and
unknown risks and uncertainties. Such risks and uncertainties may
cause actual results and future achievements of PuraMed BioScience
to be materially different than those implied by these
forward-looking statements. PuraMed BioScience has and undertakes
no obligation to provide public updates and revisions to these
forward-looking statements to reflect any changes in its
expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russ Mitchell
rmitchell@PuraMedBioScience.com
Phone: 715.359.6373
www.PuraMedBioScience.com
For Additional Information Pertaining to FastFunds Financial
Corporation:
FastFunds Financial Corporation
Mr. Henry Fong
President and Chief Executive Officer
Phone: 561.514.9042
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/puramed-bioscience-completes-distribution-agreement-with-fastfunds-financial-corporation-for-its-migraine-relief-product-300006588.html
SOURCE PuraMed BioScience, Inc.